6 Mar 2017 12:48
Vectura Group plc
Board Change
Trevor Phillips, Chief Operations Officer to step down at the Annual General Meeting on 25 May 2017
Chippenham, UK - 6 March 2017: Vectura Group plc (LSE: VEC) ("Vectura", "the Group", "the Company"), an industry-leading device and formulation business for inhaled airways disease, announces that Trevor Phillips, Vectura's Chief Operations Officer and President of US Operations ("COO"), will step down from the Board at the AGM on 25 May 2017 and leave the Company on 31 May 2017.
Since joining Vectura Trevor has played an integral leadership role in Vectura's successful development, including the acquisition of Activaero in 2014 and the merger with Skyepharma in 2016.
Following the merger with Skyepharma, in which Trevor has headed up the integration activities, Trevor has additionally led the development of the Manufacturing, Device Industrialisation and Supply Chain teams of the enlarged Vectura group. A recruitment process will now commence for a suitably experienced individual to lead the Group's Supply Chain and Manufacturing operations. This new role will not be a Board position.
James Ward-Lilley, Chief Executive Officer, commented:
"I would like to extend my personal thanks to Trevor for the support he has given me and for the highly professional way in which he has carried out his role in the business. Trevor has been with Vectura since 2010 and in that time he has been a significant driver of the transition of the Group into the business it is today. Having managed the initial integration of Skyepharma and Vectura, Trevor and I agreed that the AGM would be an appropriate time for him to transition out of the Company. The Board and I would like to thank Trevor for his contribution throughout his tenure, and we wish him well in his future endeavours."
The information required to be made available under section 430(2B) of the Companies Act 2006 in relation to Trevor Phillips will be made available in the Investors section of the Company's website www.vectura.com in due course.
- Ends -
Enquiries
Vectura Group plc | +44 (0)1249 667700 | |
Andrew Derodra - Chief Financial Officer Fleur Wood - Director Communications Elizabeth Knowles - Director Investor Relations and Analysis | ||
| ||
Consilium Strategic Communications | +44 (0)20 3709 5700 | |
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson | vectura@consilium-comms.com | |
About Vectura
Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and "smart" nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC.
Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.
For further information, please visit Vectura's website at www.vectura.com.
Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.